Suppr超能文献

重症恶性疟患者中肌肉注射青蒿琥酯和蒿甲醚的比较药代动力学

Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.

作者信息

Hien T T, Davis T M E, Chuong L V, Ilett K F, Sinh D X T, Phu N H, Agus C, Chiswell G M, White N J, Farrar J

机构信息

Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Vietnam.

出版信息

Antimicrob Agents Chemother. 2004 Nov;48(11):4234-9. doi: 10.1128/AAC.48.11.4234-4239.2004.

Abstract

The first-dose pharmacokinetic properties of intramuscular (i.m.) artesunate (ARTS; 2.4 mg/kg immediately [stat], followed by 1.2 mg/kg i.m. daily) and artemether (ARM; 3.2 mg/kg i.m. stat, followed by 1.6 mg/kg i.m. daily) were compared in Vietnamese adults with severe falciparum malaria. A total of 19 patients were studied; 9 received ARTS, and 10 received ARM. ARTS was absorbed very rapidly; concentrations in plasma peaked between 1,362 and 8,388 nmol/liter (median, 5,710 nmol/liter) within 20 min of injection and then declined with a median (range) half-life (t(1/2)) of 30 (3 to 67) min. ARTS was hydrolyzed rapidly and completely to the biologically active metabolite dihydroartemisinin (DHA). Peak DHA concentrations in plasma ranged between 1,718 and 7,080 nmol/liter (median, 3,060 nmol/liter) and declined with a t(1/2) of 52 (26 to 69) min. In contrast, ARM was slowly and erratically absorbed. The absorption profile appeared biphasic. Maximum ARM concentrations in plasma ranged between 67 nmol/liter (a value close to the 50% inhibitory concentration for some Plasmodium falciparum isolates) and 1,631 nmol/liter (median, 574 nmol/liter) and occurred at a median (range) of 10 (1.5 to 24) h. There was relatively little conversion to DHA. After i.m. injection in cases of severe malaria, absorption of the water-soluble ARTS is rapid and extensive, whereas the oil-based ARM is slowly and erratically absorbed, with relatively little conversion to the more active DHA. On the basis of this pharmacological study, parenteral ARTS is preferable to ARM as an initial antimalarial therapy, particularly in the most seriously ill patients. These findings should be formally assessed by a randomized clinical trial.

摘要

在患有严重恶性疟原虫疟疾的越南成年人中,比较了肌肉注射(i.m.)青蒿琥酯(ARTS;立即静脉注射2.4mg/kg,随后每日静脉注射1.2mg/kg)和蒿甲醚(ARM;静脉注射3.2mg/kg,随后每日静脉注射1.6mg/kg)的首剂药代动力学特性。共研究了19例患者;9例接受ARTS,10例接受ARM。ARTS吸收非常迅速;注射后20分钟内血浆浓度在1362至8388nmol/升之间达到峰值(中位数为5710nmol/升),然后下降,中位数(范围)半衰期(t(1/2))为30(3至67)分钟。ARTS迅速且完全水解为具有生物活性的代谢产物双氢青蒿素(DHA)。血浆中DHA的峰值浓度在1718至7080nmol/升之间(中位数为3060nmol/升),并以52(26至69)分钟的t(1/2)下降。相比之下,ARM吸收缓慢且不稳定。吸收曲线呈双相性。血浆中ARM的最大浓度在67nmol/升(接近某些恶性疟原虫分离株的50%抑制浓度的值)至1631nmol/升之间(中位数为574nmol/升),在中位数(范围)为10(1.5至24)小时时出现。转化为DHA的量相对较少。在严重疟疾病例中进行肌肉注射后,水溶性ARTS的吸收迅速且广泛,而油基ARM的吸收缓慢且不稳定,转化为活性更高的DHA的量相对较少。基于这项药理学研究,肠外ARTS作为初始抗疟治疗优于ARM,特别是在病情最严重的患者中。这些发现应通过随机临床试验进行正式评估。

相似文献

1
Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.
Antimicrob Agents Chemother. 2004 Nov;48(11):4234-9. doi: 10.1128/AAC.48.11.4234-4239.2004.
2
Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria.
Antimicrob Agents Chemother. 2003 Dec;47(12):3795-8. doi: 10.1128/AAC.47.12.3795-3798.2003.
7
The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.
Eur J Clin Pharmacol. 2006 Dec;62(12):1003-9. doi: 10.1007/s00228-006-0203-2. Epub 2006 Nov 7.
8
Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea.
Antimicrob Agents Chemother. 2006 Mar;50(3):968-74. doi: 10.1128/AAC.50.3.968-974.2006.
9
Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria.
Br J Clin Pharmacol. 2001 Jun;51(6):541-6. doi: 10.1046/j.1365-2125.2001.01395.x.

引用本文的文献

1
Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya.
PLoS One. 2025 Apr 9;20(4):e0316334. doi: 10.1371/journal.pone.0316334. eCollection 2025.
2
Artemisinin-resistant malaria.
Clin Microbiol Rev. 2024 Dec 10;37(4):e0010924. doi: 10.1128/cmr.00109-24. Epub 2024 Oct 15.
6
Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies as Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance.
Antimicrob Agents Chemother. 2022 May 17;66(5):e0206521. doi: 10.1128/aac.02065-21. Epub 2022 Apr 13.
7
Artemisinin Binds and Inhibits the Activity of Ddi1, a Retroviral Aspartyl Protease.
Pathogens. 2021 Nov 11;10(11):1465. doi: 10.3390/pathogens10111465.
8
Comparative effects of artemether and in combination with diminazene aceturate in the treatment of experimental infection in rats.
J Parasit Dis. 2021 Sep;45(3):673-682. doi: 10.1007/s12639-021-01350-9. Epub 2021 Jan 20.
10
Advances and roadblocks in the treatment of malaria.
Br J Clin Pharmacol. 2022 Feb;88(2):374-382. doi: 10.1111/bcp.14474. Epub 2020 Aug 1.

本文引用的文献

3
A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.
Br J Clin Pharmacol. 2001 Dec;52(6):655-61. doi: 10.1046/j.1365-2125.2001.01458.x.
5
Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria.
Antimicrob Agents Chemother. 2001 Jan;45(1):181-6. doi: 10.1128/AAC.45.1.181-186.2001.
6
Pharmacokinetics of artemisinin-type compounds.
Clin Pharmacokinet. 2000 Oct;39(4):255-70. doi: 10.2165/00003088-200039040-00002.
7
Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.
Antimicrob Agents Chemother. 2000 Apr;44(4):972-7. doi: 10.1128/AAC.44.4.972-977.2000.
9
Not much progress in treatment of cerebral malaria.
Lancet. 1998 Aug 22;352(9128):594-5. doi: 10.1016/s0140-6736(05)79572-6.
10
Pharmacokinetics of intramuscular artemether in patients with severe falciparum malaria with or without acute renal failure.
Br J Clin Pharmacol. 1998 Jun;45(6):597-600. doi: 10.1046/j.1365-2125.1998.00723.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验